Title |
Point of care testing for paediatric coeliac disease in the new ESPGHAN era.
|
---|---|
Published in |
Revista Española de Enfermedades Digestivas, January 2017
|
DOI | 10.17235/reed.2017.5337/2017 |
Pubmed ID | |
Authors |
Michelle Shui Yee Lau, David S Sanders |
Abstract |
One of the challenges in coeliac disease is the significant under-diagnosis despite the increasing prevalence and international guidelines for serological screening in appropriate patient cohorts. Several point-of-care tests for coeliac disease have been developed over the past decade with the aim of improving case detection using rapid and convenient testing. Most point-of-care tests, such as Biocard, detect anti-tissue transglutaminase (tTG) IgA antibodies, whereas Simtomax uniquely detects anti-deamidated gliadin peptide (DGP) IgA/IgG antibodies. A recent head-to-head trial in adults comparing two tTG-based point-of-care tests (Biocard and Celiac Quick Test) and Simtomax found that Simtomax was superior to Biocard and Celiac Quick Test, with sensitivities of 92.7%, 72.2% and 77.8%, respectively. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 9 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 2 | 22% |
Professor > Associate Professor | 1 | 11% |
Student > Doctoral Student | 1 | 11% |
Student > Master | 1 | 11% |
Unknown | 4 | 44% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 3 | 33% |
Linguistics | 1 | 11% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 11% |
Unknown | 4 | 44% |